Agents to Treat Airway Disease

DrugDrug NameDrug Indication
DB08897AclidiniumAclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
DB01001SalbutamolSalbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm [FDA Label, F3265, F3268].
DB01274ArformoterolA bronchodilator used for the long term, symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
DB01408BambuterolFor the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
DB00394Beclomethasone dipropionateUsed in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease.
DB01222BudesonideThe oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.
DB01410CiclesonideFor the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
DB01288FenoterolFenoterol is used for the treatment of asthma.
DB00180FlunisolideFor the maintenance treatment of asthma as a prophylactic therapy.
DB08906Fluticasone furoateFluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label][F4364]. The fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitis[FDA Label][A177130].
DB00588Fluticasone propionateFluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. A fluticasone propionate nasal spray is indicated for managing nonallergic rhinitis[F4358].
DB00983FormoterolFor use as long-term maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma, who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a short-acting bronchodilator. Not indicated for asthma that can be successfully managed with occasional use of an inhaled, short-acting beta2-adrenergic agonist. Also used for the prevention of exercise-induced bronchospasm, as well as long-term treatment of bronchospasm associated with COPD.
DB05039IndacaterolFor the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
DB00332IpratropiumInhaled ipratropium is indicated in combination with inhaled beta-agonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatment.[A176939] Asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flow.[L5900] As a single agent, ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older. It does not alleviate nasal congestion nor sneezing.[FDA label] Rhinorrhea refers to recurrent or chronic watery nasal discharge. This condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burden.[L5903] Additionally, ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.[FDA label] The chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness. As this includes several conditions, the etiology, symptoms, and treatments are diverse.[L5906] Ipratropium has also been studied to be used for the treatment of sialorrhea.[A176942] Sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivation.[A176963]
DB13139LevosalbutamolIndicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma.
DB00816OrciprenalineFor the treatment of bronchospasm, chronic bronchitis, asthma, and emphysema.
DB00764MometasoneThe inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
DB00471MontelukastMontelukast is indicated for: (a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304]; (b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and (c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307]. Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331] Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328] Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an 'as required' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]
DB09080OlodaterolOlodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
DB00043OmalizumabThis drug is an anti-IgE antibody indicated for: 1. Moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids [FDA label] 2. Chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment [FDA label]
DB01291PirbuterolFor the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma.
DB01411PranlukastUsed as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
DB01656RoflumilastRoflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.
DB00938SalmeterolFor the treatment of asthma and chronic obstructive pulmonary disease (COPD).
DB00871TerbutalineFor the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.
DB01409TiotropiumUsed in the management of chronic obstructive pulmonary disease (COPD).
DB00620TriamcinoloneFor the treatment of perennial and seasonal allergic rhinitis.
DB12248TulobuterolNot Available
DB09076UmeclidiniumIndicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
DB09082VilanterolVilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename Breo Ellipta and in combination with umeclidinium bromide as Anoro Ellipta. Approved by the FDA in 2013, use of Breo Ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.
DB00549ZafirlukastFor the prophylaxis and chronic treatment of asthma.
DB00744ZileutonFor the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
DB01407ClenbuterolUsed as a bronchodilator in the treatment of asthma patients.
DB06814ProtokylolNot Available
DrugDrug NameTargetType
DB08897AclidiniumMuscarinic acetylcholine receptor M1target
DB08897AclidiniumMuscarinic acetylcholine receptor M2target
DB08897AclidiniumMuscarinic acetylcholine receptor M3target
DB08897AclidiniumMuscarinic acetylcholine receptor M4target
DB08897AclidiniumMuscarinic acetylcholine receptor M5target
DB08897AclidiniumCholinesteraseenzyme
DB01001SalbutamolBeta-2 adrenergic receptortarget
DB01001SalbutamolBeta-1 adrenergic receptortarget
DB01001SalbutamolCytochrome P450 3A4enzyme
DB01001SalbutamolBeta-3 adrenergic receptortarget
DB01274ArformoterolBeta-2 adrenergic receptortarget
DB01274ArformoterolCytochrome P450 2D6enzyme
DB01274ArformoterolCytochrome P450 2C19enzyme
DB01274ArformoterolCytochrome P450 2A6enzyme
DB01274ArformoterolCytochrome P450 2C9enzyme
DB01408BambuterolBeta-2 adrenergic receptortarget
DB01408BambuterolCholinesteraseenzyme
DB00394Beclomethasone dipropionateCorticosteroid-binding globulincarrier
DB00394Beclomethasone dipropionateGlucocorticoid receptortarget
DB00394Beclomethasone dipropionateCytochrome P450 3A5enzyme
DB00394Beclomethasone dipropionateCytochrome P450 3A4enzyme
DB01222BudesonideGlucocorticoid receptortarget
DB01222BudesonideCytochrome P450 3A4enzyme
DB01222BudesonideCytochrome P450 3A5enzyme
DB01222BudesonideBile salt export pumptransporter
DB01410CiclesonideCorticosteroid-binding globulincarrier
DB01410CiclesonideCytochrome P450 3A4enzyme
DB01410CiclesonideCytochrome P450 2D6enzyme
DB01410CiclesonideGlucocorticoid receptortarget
DB01410CiclesonideLiver carboxylesterase 1enzyme
DB01288FenoterolBeta-2 adrenergic receptortarget
DB01288FenoterolBeta-1 adrenergic receptortarget
DB01288FenoterolBeta-3 adrenergic receptortarget
DB00180FlunisolideCorticosteroid-binding globulincarrier
DB00180FlunisolideGlucocorticoid receptortarget
DB00180FlunisolideCytochrome P450 3A4enzyme
DB08906Fluticasone furoateCytochrome P450 3A4enzyme
DB08906Fluticasone furoateGlucocorticoid receptortarget
DB08906Fluticasone furoateMultidrug resistance protein 1transporter
DB08906Fluticasone furoateCytochrome P450 2C8enzyme
DB08906Fluticasone furoateSolute carrier organic anion transporter family member 1B1transporter
DB08906Fluticasone furoateCorticosteroid-binding globulincarrier
DB08906Fluticasone furoateMultidrug resistance protein 1carrier
DB08906Fluticasone furoateSolute carrier organic anion transporter family member 1B1carrier
DB08906Fluticasone furoateCytochrome P450 3A5enzyme
DB08906Fluticasone furoateCytochrome P450 3A7enzyme
DB08906Fluticasone furoateProgesterone receptortarget
DB08906Fluticasone furoateMineralocorticoid receptortarget
DB00588Fluticasone propionateCorticosteroid-binding globulincarrier
DB00588Fluticasone propionateCytosolic phospholipase A2target
DB00588Fluticasone propionateGlucocorticoid receptortarget
DB00588Fluticasone propionateCytochrome P450 3A4enzyme
DB00588Fluticasone propionateProgesterone receptortarget
DB00588Fluticasone propionateMineralocorticoid receptortarget
DB00588Fluticasone propionateCytochrome P450 3A5enzyme
DB00588Fluticasone propionateCytochrome P450 3A7enzyme
DB00588Fluticasone propionateCytochrome P450 2C8enzyme
DB00588Fluticasone propionateMultidrug resistance protein 1carrier
DB00588Fluticasone propionateSolute carrier organic anion transporter family member 1B1carrier
DB00983FormoterolBeta-2 adrenergic receptortarget
DB00983FormoterolCytochrome P450 2C19enzyme
DB00983FormoterolCytochrome P450 2C9enzyme
DB00983FormoterolCytochrome P450 2D6enzyme
DB00983FormoterolCytochrome P450 2A6enzyme
DB00983FormoterolBeta-1 adrenergic receptortarget
DB00983FormoterolBeta-3 adrenergic receptortarget
DB05039IndacaterolBeta-2 adrenergic receptortarget
DB05039IndacaterolCytochrome P450 3A4enzyme
DB05039IndacaterolUDP-glucuronosyltransferase 1-1enzyme
DB05039IndacaterolMultidrug resistance protein 1transporter
DB00332IpratropiumMuscarinic acetylcholine receptor M1target
DB00332IpratropiumMuscarinic acetylcholine receptor M2target
DB00332IpratropiumMuscarinic acetylcholine receptor M3target
DB00332IpratropiumSolute carrier family 22 member 5transporter
DB00332IpratropiumSolute carrier family 22 member 4transporter
DB00332IpratropiumSerum albumincarrier
DB00332Ipratropiumalpha1-acid glycoproteincarrier
DB13139LevosalbutamolBeta-2 adrenergic receptortarget
DB13139LevosalbutamolCytochrome P450 3A4enzyme
DB13139LevosalbutamolCytochrome P450 2D6enzyme
DB13139LevosalbutamolSolute carrier organic anion transporter family member 1B1transporter
DB13139LevosalbutamolSolute carrier organic anion transporter family member 1B3transporter
DB00816OrciprenalineBeta-2 adrenergic receptortarget
DB00764MometasoneGlucocorticoid receptortarget
DB00764MometasoneCytochrome P450 2C8enzyme
DB00764MometasoneProgesterone receptortarget
DB00764MometasoneCytochrome P450 3A4enzyme
DB00471MontelukastCysteinyl leukotriene receptor 1target
DB00471MontelukastArachidonate 5-lipoxygenasetarget
DB00471MontelukastCytochrome P450 3A4enzyme
DB00471MontelukastCytochrome P450 2C9enzyme
DB00471MontelukastCytochrome P450 2C8enzyme
DB00471MontelukastSolute carrier organic anion transporter family member 2B1transporter
DB00471MontelukastProstaglandin G/H synthase 1enzyme
DB00471MontelukastCytochrome P450 2A6enzyme
DB09080OlodaterolBeta-2 adrenergic receptortarget
DB09080OlodaterolCytochrome P450 2C9enzyme
DB09080OlodaterolCytochrome P450 2C8enzyme
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
DB01291PirbuterolBeta-2 adrenergic receptortarget
DB01291PirbuterolBeta-1 adrenergic receptortarget
DB01411PranlukastTumor necrosis factortarget
DB01411PranlukastInterleukin-5target
DB01411PranlukastEosinophil cationic proteintarget
DB01411PranlukastNuclear factor NF-kappa-B p105 subunittarget
DB01411PranlukastMucin-2target
DB01411PranlukastCysteinyl leukotriene receptor 1target
DB01411PranlukastCytochrome P450 3A4enzyme
DB01411PranlukastCanalicular multispecific organic anion transporter 1transporter
DB01411PranlukastCytochrome P450 2C9enzyme
DB01656RoflumilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB01656RoflumilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB01656RoflumilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB01656RoflumilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Ctarget
DB01656RoflumilastCytochrome P450 3A4enzyme
DB00938SalmeterolBeta-2 adrenergic receptortarget
DB00938SalmeterolCytochrome P450 3A4enzyme
DB00938SalmeterolCytochrome P450 2C8enzyme
DB00938SalmeterolCytochrome P450 3A5enzyme
DB00938SalmeterolCytochrome P450 3A7enzyme
DB00938SalmeterolBeta-1 adrenergic receptortarget
DB00938SalmeterolBeta-3 adrenergic receptortarget
DB00871TerbutalineBeta-2 adrenergic receptortarget
DB00871TerbutalineCholinesteraseenzyme
DB00871TerbutalineBeta-3 adrenergic receptortarget
DB00871TerbutalineBeta-1 adrenergic receptortarget
DB01409TiotropiumMuscarinic acetylcholine receptor M3target
DB01409TiotropiumCytochrome P450 2D6enzyme
DB01409TiotropiumCytochrome P450 3A4enzyme
DB01409TiotropiumMuscarinic acetylcholine receptor M1target
DB01409TiotropiumMuscarinic acetylcholine receptor M2target
DB01409TiotropiumSolute carrier family 22 member 5transporter
DB01409TiotropiumSolute carrier family 22 member 4transporter
DB01409TiotropiumMuscarinic acetylcholine receptor M4target
DB01409TiotropiumMuscarinic acetylcholine receptor M5target
DB00620TriamcinoloneCorticosteroid-binding globulincarrier
DB00620TriamcinoloneGlucocorticoid receptortarget
DB00620TriamcinoloneCytochrome P450 3A4enzyme
DB00620TriamcinoloneProstaglandin G/H synthase 2enzyme
DB00620TriamcinoloneCholinesteraseenzyme
DB12248TulobuterolBeta-2 adrenergic receptortarget
DB09076UmeclidiniumMuscarinic acetylcholine receptor M1target
DB09076UmeclidiniumMuscarinic acetylcholine receptor M2target
DB09076UmeclidiniumMuscarinic acetylcholine receptor M3target
DB09076UmeclidiniumMuscarinic acetylcholine receptor M4target
DB09076UmeclidiniumMuscarinic acetylcholine receptor M5target
DB09076UmeclidiniumCytochrome P450 2D6enzyme
DB09076UmeclidiniumMultidrug resistance protein 1transporter
DB09082VilanterolCytochrome P450 3A4enzyme
DB09082VilanterolBeta-2 adrenergic receptortarget
DB00549ZafirlukastCysteinyl leukotriene receptor 1target
DB00549ZafirlukastCytochrome P450 2C9enzyme
DB00549ZafirlukastCytochrome P450 2C8enzyme
DB00549ZafirlukastProstaglandin G/H synthase 1enzyme
DB00549ZafirlukastCytochrome P450 3A4enzyme
DB00549ZafirlukastCytochrome P450 1A2enzyme
DB00549ZafirlukastCytochrome P450 2C19enzyme
DB00549ZafirlukastCytochrome P450 2E1enzyme
DB00549ZafirlukastATP-binding cassette sub-family G member 2transporter
DB00744ZileutonArachidonate 5-lipoxygenasetarget
DB00744ZileutonCytochrome P450 2C9enzyme
DB00744ZileutonCytochrome P450 1A2enzyme
DB00744ZileutonCytochrome P450 3A4enzyme
DB00744ZileutonProstaglandin G/H synthase 1enzyme
DB00744ZileutonUDP-glucuronosyltransferase 1-9enzyme
DB00744ZileutonSerum albumincarrier
DB01407ClenbuterolBeta-2 adrenergic receptortarget
DB01407ClenbuterolBeta-nerve growth factortarget
DB01407ClenbuterolTumor necrosis factortarget
DB01407ClenbuterolBeta-1 adrenergic receptortarget
DB01407ClenbuterolBeta-3 adrenergic receptortarget
DB01407ClenbuterolCytochrome P450 1A1enzyme
DB06814ProtokylolBeta-2 adrenergic receptortarget